van Maren, M.A.
Wyers, C.E. http://orcid.org/0000-0001-7662-3990
Driessen, J.H.M.
Visser, J.V.
de Vries, F.
van de Wijdeven, K.
Gevers, S.
Lems, W.F.
Emmelot-Vonk, M.H.
van den Bergh, J.P.W.
Funding for this research was provided by:
Interdisciplinary working group osteoporosis foundation (Not applicable)
Article History
Received: 27 December 2018
Accepted: 6 June 2019
First Online: 18 July 2019
Compliance with ethical standards
:
: Maud van Maren has no disclosures.Caroline E. Wyers has no disclosures.Johanna H.M. Driessen has no disclosures.Jonathan V. Visser is employed at ApotheekZorg. ApotheekZorg receives financial support from Eli Lilly Nederland B.V. to perform the patient support program and to fund this study.Frank de Vries supervises two PhD students who are employed by F. Hoffmann La Roche Ltd. (Basel, Switzerland and Welwyn Garden City, UK). The topics of these PhDs are not related to the current study manuscript and he has not received any fees or reimbursements for this.Katrien van de Wijdeven is employed at ApotheekZorg. ApotheekZorg receives financial support from Eli Lilly Nederland B.V. to perform the patient support program and to fund this study.Sonja Gevers is employed at ApotheekZorg. ApotheekZorg receives financial support from Eli Lilly Nederland B.V. to perform the patient support program and to fund this study.Willem F. Lems: Speakers fee/advisory boards Amgen, Eli Lilly, Merck.Marielle H. Emmelot Vonk: Speakers fee/advisory boards Amgen, Eli Lilly.Joop P.W. van den Bergh: Speakers fee/advisory boards Amgen, Eli Lilly, UCB, Sanofi.